S36ɳÁú»á

¿ËÈÕ£¬£¬
£¬£¬£¬Õã½­´óѧҽѧԺ/Á¼ä¾ÊµÑéÊÒÇ®ÅôÐñÑо¿Ô±¡¢Õã½­´óѧҽѧԺÁ¥ÊôµÚÒ»Ò½Ôº/Á¼ä¾ÊµÑéÊһƺӽÌÊÚÅäºÏÔÚ¹ú¼ÊÆÚ¿¯Cell ReportsÉϽÒÏþÌâΪ¡°Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway¡±µÄÑо¿ÂÛÎÄ¡£¡£¡£¡£¸ÃÂÛÎÄÑо¿Ð§¹ûÅú×¢£¬£¬
£¬£¬£¬ÔÚCAR-Tϸ°ûÖУ¬£¬
£¬£¬£¬ÌØÊâÊÇM344ºÍchidamide£¬£¬
£¬£¬£¬Ê¹ÓÃIÀàHDACi¾ÙÐбí¹ÛÒÅ´«¸ÉÔ¤£¬£¬
£¬£¬£¬¿ÉÒÔÌá¸ß¿¹Ö×Áö¹¦Ð§£¬£¬
£¬£¬£¬ÐγɸüºÃµÄÓ°ÏóÁ¦ºÍ¿¹Ë¥½ßÄÜÁ¦¡£¡£¡£¡£

Ñо¿Åä¾°

ǶºÏ¿¹Ô­ÊÜÌåT£¨CAR-T£©Ï¸°ûÓÉ¿¹Ô­Á¬Ïµµ¥Á´¿É±äƬ¶Ï£¨scFv£©¡¢½ÂÁ´/¿çĤ½á¹¹Óò¡¢Ï¸°ûÄڴ̼¤½á¹¹Óò£¨ÈçCD28ºÍ4-1BB£©ºÍCD3¦Æ×é³É£¬£¬
£¬£¬£¬ÔÚѪҺϵͳ¶ñÐÔÖ×ÁöµÄÁÙ´²ÖÎÁÆÖÐÈ¡µÃÁËÏÔÖøµÄÀֳɡ£¡£¡£¡£Ö»¹ÜÔÆÔÆ£¬£¬
£¬£¬£¬ÓÉÓÚCAR-Tϸ°ûºÄ½ßºÍ¹¦Ð§ÕÏ°­µ¼ÖµÄÖÎÁƺóÄÍÒ©ÐԺ͸´·¢Í¨³£»£»£»£»áµ¼ÖÂÁîÈ˾ÚÉ¥µÄÁÙ´²Ð§¹û¡£¡£¡£¡£×î½üµÄÑо¿Åú×¢£¬£¬
£¬£¬£¬³¤ÊÙÃüµÄÓ°ÏóCAR-Tϸ°ûÓëCAR-Tϸ°ûÖÎÁƺó»¼Õߵij¤ÆÚÐÔÑÓÉì¡¢Ö×Áö¼à²â¸üÇ¿ºÍÉúÑÄÂÊÌá¸ßÓйØ¡£¡£¡£¡£È»¶ø£¬£¬
£¬£¬£¬CAR-Tϸ°ûºÄ½ßºÍÓ°ÏóDZÁ¦µÄDZÔÚ»úÖÆÔںܺéÁ÷ƽÉÏÈÔȻģºý²»Çå¡£¡£¡£¡£

CAR-T ϸ°ûºÄ½ßµÄÌØÕ÷ÊÇÔöÖ³ºÍϸ°û¶¾ÐÔ½µµÍ£¬£¬
£¬£¬£¬ÒÖÖÆÐÔÊÜÌå±í´ïÉϵ÷£¬£¬
£¬£¬£¬Ö÷ÒªÓÉÂýÐÔ¿¹Ô­µÄÒ»Á¬´Ì¼¤»ò CAR ×ÔȺ¼¯µÄÇ¿Ö±ÐźÅÓÕµ¼¡£¡£¡£¡£Ô½À´Ô½¶àµÄÖ¤¾ÝÅú×¢£¬£¬
£¬£¬£¬±í¹ÛÒÅ´«×÷ΪһÖÖÏÈÌì»úÖƵ÷ÀíCAR-Tϸ°û¹¦Ð§ÕÏ°­¡£¡£¡£¡£±í¹ÛÒÅ´«ÐÞÊΰüÀ¨È¾É«ÖÊÖØËÜ¡¢×éÂÑ°×ÒÒõ£»£»£»£»¯¡¢DNA ¼×»ù»¯ºÍ RNA ÐÞÊΣ¬£¬
£¬£¬£¬ËüÃǼÓÈë¾öÒéϸ°ûÔËÆøºÍÓ°Ïì T ϸ°û¹¦Ð§µÄת¼µ÷¿Ø¡£¡£¡£¡£Í¨¹ý»ùÒò±à¼­»òÒ©Îï¾ÙÐбí¹ÛÒÅ´«¸ÉÔ¤£¬£¬
£¬£¬£¬ÓÐÓÃÔöÇ¿ÁËCAR-Tϸ°û¶ÔÖÕÄ©ºÄ½ßµÄ¶Ô¿¹Á¦¡£¡£¡£¡£ÔÚ֮ǰµÄÑо¿ÖУ¬£¬
£¬£¬£¬¿Æѧ¼ÒÃÇÆÊÎöÁËȾɫÖʿɼ°ÐÔºÍCAR-Tϸ°ûºÄ½ßÀú³ÌÖÐÉæ¼°µÄÒªº¦×ªÂ¼Òò×ÓµÄ×ۺ϶¯Ì¬µ¥Ï¸°û¾°¹Û¡£¡£¡£¡£Òò´Ë£¬£¬
£¬£¬£¬Ì½Ë÷ͨ¹ý±í¹ÛÒÅ´«ÖØËܸÄÉÆCAR-Tϸ°û¹¦Ð§µÄÐÂÕ½ÂÔÖµµÃ½øÒ»²½Ñо¿¡£¡£¡£¡£

×éÂÑ°×ÍÑÒÒõ£Ã¸ £¨HDAC£© Óë×éÂÑ°×ÒÒõ£×ªÒÆø £¨HAT£© ¶Ô¿¹×éÂÑ°×ÒÒõ£»£»£»£»¯µÄ¶¯Ì¬Æ½ºâ£¬£¬
£¬£¬£¬ËüÃÇÅäºÏµ÷ÀíȾɫÖʿɼ°ÐÔºÍÏÂÓλùÒòת¼¡£¡£¡£¡£HDAC¿ÉÒÔƾ֤ÆäÔÚ»îÐÔø½á¹¹ÓòÖеĽø»¯ÊؾÉÐÔºÍÏàËÆÐÔ·ÖΪÁ½¸öÖ÷ÒªÑÇȺºÍÎå¸ö²î±ðµÄÖֱ𡣡£¡£¡£Ï¸°û¶¾ÐÔ T ÁÜ°Íϸ°û £¨CTL£© ºÍÖ×Áö½þÈóÁÜ°Íϸ°û £¨TIL£© ÖеĿ¹Ö×Áö»îÐÔÔöÇ¿¿ÉÒÔͨ¹ýÒÖÖÆ HDAC »òÔöÌí×éÂÑ°×ÒÒõ£»£»£»£»¯À´ÊµÏÖ¡£¡£¡£¡£HDACÒÖÖƼÁ£¨HDACi£©ÊÇÒ»×éС·Ö×ÓÒ©Î£¬
£¬£¬£¬¿ÉÌØÒìÐÔÒÖÖÆHDAC¶Ô×éÂѰ׵ĻîÐÔ¡£¡£¡£¡£Î¢ÉúÎï¶ÌÁ´Ö¬·¾ËáµÄ´úлµ÷Àí»¹Í¨¹ý¼¤»îmTOR£¨²¸È鶯ÎïÀ×ÅÁùËذб꣩ÐźÅͨ·ÒÖÖÆCD8 Tϸ°ûµÄHDAC»îÐÔºÍÔöǿЧӦ¹¦Ð§¡£¡£¡£¡£È»¶ø£¬£¬
£¬£¬£¬CAR-Tϸ°ûÓëHDACiµÄÁ¬ÏµÊ©Õ¹Ð­Í¬¿¹Ö×Áö×÷ÓÃÉÐδÃ÷È·¡£¡£¡£¡£

Ñо¿Ð§¹û

±¾Ñо¿£¬£¬
£¬£¬£¬¿Æѧ¼ÒÃÇͨ¹ý¶ÔȾɫÖÊÐÞÊÎÒ©ÎïµÄ¸ßͨÁ¿É¸Ñ¡£¬£¬
£¬£¬£¬½«IÀà×éÂÑ°×ÍÑÒÒõ£Ã¸ÒÖÖƼÁ £¨HDACi£©ÅжÏΪCAR-Tϸ°û¹¦Ð§µÄÔöÇ¿¼Á£¬£¬
£¬£¬£¬ÆäÖÐM344ºÍÆæ´ïõ£°·£¨chidamide£©ÔöÇ¿ÁËCAR-Tϸ°ûµÄÓ°Ïóά³ÖºÍ¶ÔºÄ½ßµÄ¶Ô¿¹Á¦£¬£¬
£¬£¬£¬´Ó¶øÔÚÌåÍâºÍÌåÄÚÓÕµ¼Ò»Á¬µÄ¿¹Ö×Áö¹¦Ð§¡£¡£¡£¡£´Ó»úÖÆÉϽ²HDACi½µµÍHDAC1±í´ï²¢ÔöÇ¿H3K27ac»îÐÔ¡£¡£¡£¡£À´×ÔRNA-seq¡¢ATAC-seqºÍH3K27ac CUT&Tag-seq µÄ¶à×éѧÆÊÎöÅú×¢£¬£¬
£¬£¬£¬HDACiÉϵ÷TCF4¡¢LEF1ºÍCTNNB1µÄ±í´ï£¬£¬
£¬£¬£¬Ëæºó¼¤»î¾­µäµÄWnt/¦Â-catenin ͨ·¡£¡£¡£¡£×ÜÖ®£¬£¬
£¬£¬£¬Ñо¿Ð§¹ûÆÊÎöÁËIÀàHDACiÔÚÔöÇ¿CAR-Tϸ°û¹¦Ð§ÖеĹ¦Ð§×÷Ó㬣¬
£¬£¬£¬ÎªCAR-Tϸ°ûÖÎÁÆÓëHDACiÖÎÁƵÄЭͬ×éºÏÌṩÁË»ù´¡ºÍÖÎÁưеã¡£¡£¡£¡£

Ñо¿½áÂÛ

¸ÃÑо¿Ð§¹ûÌṩÁËÁîÈËÐÅ·þµÄÖ¤¾Ý£¬£¬
£¬£¬£¬Ö¤ÊµHDACi£¬£¬
£¬£¬£¬ÌØÊâÊÇM344ºÍchidamide£¬£¬
£¬£¬£¬Í¨¹ý±í¹ÛÒÅ´«ÖØËܺͼ¤»î¾­µäWntÐźÅͨ·£¬£¬
£¬£¬£¬ÔÚÇ¿Ö±ÐźŴ«µ¼ºÍ¿¹Ô­Ì»Â¶Ï£¬£¬
£¬£¬£¬Í¨¹ýά³ÖÓ°Ïó±íÐͺÍïÔÌ­CAR-Tϸ°ûµÄºÄ½ß¡£¡£¡£¡£CAR-Tϸ°ûÁÆ·¨ÓëHDACiά³ÖÁÆ·¨µÄÁ¬ÏµÔÚʵÏÖ¸üºÃµÄÁÙ´²ÁÆЧ·½Ãæ¾ßÓÐÁÉÀ«µÄÔ¶¾°¡£¡£¡£¡£Î´À´£¬£¬
£¬£¬£¬¶à×éѧÊÖÒÕµÄÔËÓý«Îª¿Æѧ¼ÒÃÇÖÜÈ«ÏàʶCAR-Tϸ°ûÉúÎïѧ¹¦Ð§µÄ¶¯Ì¬×ª±ä£¬£¬
£¬£¬£¬Ì½Ë÷еÄÖÎÁưеãºÍ¸ÉÔ¤Õ½ÂÔÌṩÁ¢ÒìÊӽǡ£¡£¡£¡£